Single pivotal trials with few corroborating characteristics were used for FDA approval of cancer therapies
<p><strong>Background and objective </strong>Novel cancer therapies are often approved with evidence from a single pivotal trial alone. There are concerns about the credibility of this evidence. Higher validity may be indicated by five methodological and statistical characteristics...
Main Authors: | Aviv, L, Speich, B, Matthias, B, Francesco, S, Heiner C, B, Arnav, A, John P.A., I, Tiago V., P, Benjamin, K, Lars G, H |
---|---|
Format: | Journal article |
Language: | English |
Published: |
Elsevier
2019
|
Similar Items
-
Why Are There So Few FDA-Approved Therapeutics for Wound Healing?
by: Mei Chen, et al.
Published: (2023-10-01) -
You can now search FDA approval documents easily at fda.opentrials.net
by: Goldacre, B, et al.
Published: (2017) -
Characteristics of pivotal clinical trials of FDA-approved endovascular devices between 2000 and 2018: An interrupted time series analysis
by: John T. Moon, et al.
Published: (2023-01-01) -
FDA Approvals of Biologics in 2022
by: Alexander C. Martins, et al.
Published: (2023-05-01) -
Corroborating evidence-based medicine
by: Mebius, A
Published: (2014)